A simulation study of finite-sample properties of marginal structural Cox proportional hazards models

Statistics in Medicine

Volumn 31, Issue 19, 2012, Pages 2098-2109

  Westreich, Daniel ^a   Cole, Stephen R ^b   Schisterman, Enrique F ^c   Platt, Robert W ^d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Bias; Causal inference; Marginal structural models; Monte Carlo study

Indexed keywords

ANTIRETROVIRUS AGENT;

ACCURACY; ARTICLE; ERROR; FINITE SAMPLE PROPERTY; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; INTERNAL BIAS; MARGINAL STRUCTURAL COX PROPORTIONAL HAZARDS MODEL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; ROOT MEAN SQUARED ERROR; SAMPLE SIZE; SIMULATION; STANDARD ERROR; STATISTICAL PARAMETERS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIAS (EPIDEMIOLOGY); BINOMIAL DISTRIBUTION; COMPUTER SIMULATION; CONFIDENCE INTERVALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HIV INFECTIONS; HUMANS; MALE; MONTE CARLO METHOD; MULTICENTER STUDIES AS TOPIC; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84863991676     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5317     Document Type: Article

References (42)

1. Robins JM. HYPERLINK "http://biosun1.harvard.edu/~robins/msm-web.pdf" Marginal structural models. 1997 Proceedings of the American Statistical Association, 1998. Section on Bayesian Statistical Science, pp. 1-10. Reproduced courtesy of the American Statistical Association.
2. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570.
3. Hernán MA, Brumback BA, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. JASA 2001; 96:440-448(449).
4. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173-1177.
5. Cook NR, Cole SR, Hennekens CH. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. American Journal of Epidemiology 2002; 155:1045-1053.
6. Cole S, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. American Journal of Epidemiology 2003; 158:687-694.
7. Barrón Y, Cole SR, Greenblatt RM, Cohen MH, Anastos K, DeHovitz JA, et al. Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. AIDS 2004; 18:1579-1584.
8. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P. et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378-384.
9. Wang C, Vlahov D, Galai N, Cole SR, Bareta J, Pollini R, et al. The effect of HIV infection on overdose mortality. AIDS 2005; 19:935-942.
10. Eisner MD, Wang Y, Haight TJ, Balmes J, Hammond SK, Tager IB. Secondhand smoke exposure, pulmonary function, and cardiovascular mortality. Annals of Epidemiology 2007; 17:364-373.
11. López-Gatell H, Cole SR, Hessol NA, French AL, Greenblatt RM, Landesman S, et al. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. American Journal of Epidemiology 2007; 165:1134-1142.
12. Delaney JA, Daskalopoulou SS, Suissa S. Traditional versus marginal structural models to estimate the effectiveness of beta-blocker use on mortality after myocardial infarction. Pharmacoepidemiology and Drug Safety 2009; 18:1-6.
13. López-Gatell H, Cole SR, Margolick JB, Witt MD, Martinson J, Phair JP, et al. Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. AIDS 2008; 22:1869-1873.
14. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22:2097-2106.
15. Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24:963-972.
16. Wiesbauer F, Heinze G, Mitterbauer C, Harnoncourt F, Horl WH, Oberbauer R. Statin use is associated with prolonged survival of renal transplant recipients. Journal of the American Society of Nephrology 2008; 19:2211-2218.
17. Fox MP, Brooks DR, Kuhn L, Aldrovandi G, Sinkala M, Kankasa C, et al. Role of breastfeeding cessation in mediating the relationship between maternal HIV disease stage and increased child mortality among HIV-exposed uninfected children. International Journal of Epidemiology 2009; 38:569-576.
18. Westreich D, MacPhail P, Van Rie A, Malope-Kgokong B, Ive P, Rubel D, et al. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS 2009; 23:707-715.
19. Westreich DJ, Sanne I, Maskew M, Malope-Kgokong B, Conradie F, Majuba P, et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clinical Infectious Diseases 2009; 48:1617-1623.
20. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society. Series B (Methodological) 1972; 34:187-220.
21. Cole SR, Frangakis CE. The consistency statement in causal inference: a definition or an assumption? Epidemiology 2009; 20:3-5.
22. Mortimer KM, Neugebauer R, van der Laan M, Tager IB. An application of model-fitting procedures for marginal structural models. American Journal of Epidemiology 2005; 162:382-388.
23. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. American Journal of Epidemiology 2008; 168:656-664.
24. Robins JM. Marginal structural models versus structural nested models as tools for causal inference. In Statistical Models in Epidemiology, the Environment, and Clinical Trials. The IMA Volumes in Mathematics and its Applications, Willard Miller J (ed.). NY: Springer-Verlag, 1999; 95-134.
25. Tsiatis AA. Semiparametric Theory and Missing Data. Springer: New York, 2006.
26. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55.
27. Cole SR, Hernán MA. Adjusted survival curves with inverse probability weights. Computer Methods and Programs in Biomedicine 2004; 75:45-49.
28. Westreich D, Cole SR, Tien PC, Chmiel JS, Kingsley L, Funk MJ, et al. Time scale and adjusted survival curves for marginal structural Cox models. American Journal of Epidemiology 2010; 171(6):691-700.
29. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease, The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351:543-549.
30. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine 1997; 337:725-733.
31. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560.
32. Pearl J. Causal diagrams for empirical research. Biometrika 1995; 82:669-688.
33. Hernán MA.A definition of causal effect for epidemiological research. Journal of Epidemiology and Community Health 2004; 58:265-271.
34. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. Journal of Educational Psychology 1974; 66:688-701.
35. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, et al. Nelfinavir, efavirenz or both after the failure of nucleoside treatment of HIV infection. New England Journal of Medicine 2001; 345:398-407.
36. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 1997; 126:946-954.
37. Burton A, Altman DG, Royston P. The design of simulation studies in medical statistics. Statistics in Medicine 2006; 25:4279-4292.
38. Greenland S. Absence of confounding does not correspond to collapsibility of the rate ratio or rate difference. Epidemiology 1996; 7:498-501.
39. Young JG, Hernán MA, Picciotto S, Robins JM. Simulation from structural survival models under complex time-varying data structures. Joint Statistical Meeting, Denver, CO, 2019.
40. Bodnar LM, Davidian M, Siega-Riz AM, Tsiatis AA. Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology. American Journal of Epidemiology 2004; 159:926-934.
41. Young JG, Hernan MA, Picciotto S, Robins JM. Relation between three classes of structural models for the effect of a time-varying exposure on survival. Lifetime Data Analysis 2010; 16:71-84.
42. Taubman SL, Robins JM, Mittleman MA, Hernan MA. Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol 2009; 38:1599-1611.